Blood and Saliva Sample Collection for AREDS 2
| Status: | Completed |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 55 - 85 |
| Updated: | 4/21/2017 |
| Start Date: | February 24, 2012 |
| End Date: | February 5, 2013 |
Blood and Saliva Sample Collection and Submission to the Age-Related Eye Disease Study 2 (AREDS2) Genetic Repository
Background:
- The Age-Related Eye Disease Study 2 (AREDS 2) is looking at different eye diseases. Study
participants will provide blood and saliva samples. The samples will be stored for research
on eye diseases.
Objectives:
- To collect blood and saliva samples for AREDS 2 research.
Eligibility:
- AREDS 2 research study participants.
Design:
- Participants will provide blood and saliva samples.
- The samples will be submitted with personal and medical information. This information
will be collected during the AREDS 2 procedures.
- The Age-Related Eye Disease Study 2 (AREDS 2) is looking at different eye diseases. Study
participants will provide blood and saliva samples. The samples will be stored for research
on eye diseases.
Objectives:
- To collect blood and saliva samples for AREDS 2 research.
Eligibility:
- AREDS 2 research study participants.
Design:
- Participants will provide blood and saliva samples.
- The samples will be submitted with personal and medical information. This information
will be collected during the AREDS 2 procedures.
AREDS2 is a multi-center, Phase III, randomized clinical trial designed to assess the
effects of oral supplementation of high doses of macular xanthophylls (lutein and
zeaxanthin) and/or omega-3 long-chain polyunsaturated fatty acids (LCPUFAs) as a treatment
for age-related macular degeneration (AMD), cataract and moderate vision loss. In addition
to this objective, the AREDS2 study will provide information on the clinical course,
prognosis, and risk factors for development and progression of both AMD and cataract. Other
study goals include the evaluation of eliminating beta-carotene and/or reducing zinc in the
original AREDS formulation on the progression and development of AMD. AREDS2 will also seek
to validate the fundus photographic AMD scale developed from AREDS.
The objective of this protocol is to have AREDS2 participants submit blood and saliva
samples to the AREDS2 Genetic Repository (Fisher BioServices, Rockville, MD) in order to
provide further materials for the study of the genetic and biochemical bases for eye disease
and possibly other diseases.
effects of oral supplementation of high doses of macular xanthophylls (lutein and
zeaxanthin) and/or omega-3 long-chain polyunsaturated fatty acids (LCPUFAs) as a treatment
for age-related macular degeneration (AMD), cataract and moderate vision loss. In addition
to this objective, the AREDS2 study will provide information on the clinical course,
prognosis, and risk factors for development and progression of both AMD and cataract. Other
study goals include the evaluation of eliminating beta-carotene and/or reducing zinc in the
original AREDS formulation on the progression and development of AMD. AREDS2 will also seek
to validate the fundus photographic AMD scale developed from AREDS.
The objective of this protocol is to have AREDS2 participants submit blood and saliva
samples to the AREDS2 Genetic Repository (Fisher BioServices, Rockville, MD) in order to
provide further materials for the study of the genetic and biochemical bases for eye disease
and possibly other diseases.
- INCLUSION CRITERIA:
Participants will be eligible if they were enrolled in the AREDS2 protocol and willing to
have their blood drawn and saliva collected.
EXCLUSION CRITERIA:
Participants will not be eligible if they were not enrolled in AREDS2 and are not willing
to have their blood drawn and saliva collected.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Click here to add this to my saved trials
